Our Story

Eyevance Pharmaceuticals was born out of a desire to revolutionize the eye care industry. Co-Founders Jerry St. Peter and Jason Werner had worked together in the ophthalmic space for many years leading up to their life-changing decision to form Eyevance. They noticed a therapeutic segment of the industry was largely underserved and immediately saw an opportunity to not only occupy the space, but to step up and lead it.

Jerry and Jason’s combined entrepreneurial spirits, industry experience and know-how, innovative mindsets, and drive to win made venturing out on their own a no-brainer. In September 2017, their vision was realized — and the journey had just begun.

Due to their relentless efforts and unrivaled passion, Eyevance quickly gained momentum, and is still going strong. We are proud to have built a culture much like Jerry and Jason themselves, centered around entrepreneurship, hard work, and tenacity. Consequently, the Eyevance team has been unstoppable.

Eyevance was founded on the concept of thinking, acting, and doing differently. We see opportunities where others don’t. We think outside the box, problem solving and innovating in unconventional ways. Everything we do centers around our customers.

We’re setting a new bar, and we’re setting it high. We believe in choosing every day to be extraordinary. We believe in living with intention and purpose and making a difference in people’s lives.

We believe it’s time for an eye care revolution.

Company Timeline

September 1, 2017

Eyevance formation by Co-Founders Jerry St. Peter and Jason Werner; initial financing

September 1, 2017

September 2017

First business development deal – licensed ZERVIATE™ from Nicox

September 2017

December 2017

Acquired first innovative development stage program – VISOVANQ™ from Kurobe

December 2017

February 2018

Hired Chief Scientific Officer, Mark C. Jasek, PhD

February 2018

April 2018

Hired Chief Financial Officer, Wes Brazell

April 2018

May 2018

Hired Vice President of Sales, Brent Jones
May 2018

September 2018

Acquired FRESHKOTE® Preservative Free (PF) Tear Lubricant from Focus Laboratories 

September 2018

October 2018

Acquired FLAREX® from Novartis
October 2018

October 2018

Acquired NEXAGON® – an innovative, rare disease ophthalmic program – from OcuNexus Therapeutics

October 2018

December 2018

Hired nationwide team of Ophthalmic Territory Managers
December 2018

December 2018

Acquired three non-disclosed, FDA approved NDAs

December 2018

February 2019

U.S. commercial launch of FLAREX® and FRESHKOTE® PF
February 2019

October 2019

Acquired TOBRADEX® ST and NATACYN® from Novartis; completed finance transaction to fully fund Eyevance

October 2019

February 2020

Hired Chief Commercial Officer, Julie Speed
February 2020

March 2020

U.S. launch of TOBRADEX® ST

March 2020

April 2020

U.S. launch of ZERVIATE™

April 2020